Not Yet RecruitingNot Applicable

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Switzerland50 participantsStarted 2026-06-01

Plain-language summary

An observational study tracking the clinical course of patients with IgA nephropathy.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * IgA Nephropathy, Use of Sparsentan Exclusion Criteria: * age \< 18y

Change of Albuminuria

Timeframe: 36 months

NCT IDNCT07555301

SponsorWaid City Hospital, Zurich

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12-31

Andi Schleich